文献检索

查找使用阿拉丁产品的科研文献

检索与阿拉丁产品相关的同行评审论文、DOI、PubMed 编号、期刊、作者、CAS 号及研究领域。

科研影响力快照

与阿拉丁产品相关的已发表科研成果

在搜索之前,这些指标可帮助访客快速了解产品关联科研的规模与质量。

346,364+ SCI 论文 与阿拉丁产品引用相关
2,295,288.15 总影响因子 匹配文献记录中影响因子的总和
81.20 最高期刊影响因子 匹配期刊中的最高 IF
6.63 平均期刊影响因子 匹配文献的平均 IF

参考指标 指标基于阿拉丁文献引用数据库及期刊影响因子记录。文献关联仅供科研参考,请以原始文献为准。

热门产品

视图 列表 网格

1 项目

设置提升方向
肾灌注
Contemporary Clinical Trials · 2022 · IF 2.261

Enhanced external counterpulsation: A new method to alleviate contrast-induced acute kidney injury

Xiaocong Zhang,Chun Yao,Qunlin Xiao,Jiansheng Wu,Guifu Wu

Background Contrast-induced acute kidney injury (CI-AKI) is a common complication after exposure to contrast media. Renal ischaemia occurs in the initial stage of CI-AKI, however, there are very few effective measures to improve renal perfusion . Methods A total of 114 patients with an estimated glomerular filtration rate (eGFR) of 60–89 ml/min/1.73m 2 were randomly assigned to two groups: enhanced external counterpulsation (EECP) group ( N  = 57) and control group (N = 57). Two hours after contrast exposure, EECP group received EECP treatment for 1 h while no intervention was performed control group. The primary outcome was the incidence of serum cystatin C concentration to 10% above the baseline concentration at 24 h after contrast administration. The secondary outcomes were the incidence of CI-AKI (defined as an increase in serum creatinine concentration to ≥0.5 mg/dl or by 25% compare to the baseline after contrast exposure), contrast clearance and adverse clinical events. Results The primary outcome was observed in 26 patients (6 EECP and 20 control; 11% vs. 35%; P  = 0.002). CI-AKI occurred in four patients (0 EECP and 4 control; 0% vs. 7%; P  = 0.042). The clearance rate of iopromide in the initial 3 h was significantly different between EECP and control group (59.92 ± 8.84 vs 46.80 ± 9.26 ml/min/1.73 m 2 ; P  < 0.001). No adverse clinical events were observed in this study. Conclusions This study demonstrates that EECP increases the contrast clearance and may have an effect in reducing the risk of CI-AKI. The study has been registered in Chinese Clinical Trial Registry (ChiCTR 2,000,039,190).

CAS / MDL: 75-05-8 64-18-6 67-56-1
研究领域: 肾病学 · 心脏病学 · 临床研究
✓ 已验证 产品关联 DOI PubMed 高影响因子
查看原文 查看 PubMed
已复制

文献关联基于可获得的产品、CAS、DOI 及引用记录。收录不代表作者或出版方对阿拉丁产品的背书,请以原始文献为准。